SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Astellas Pharma Inc. (ALPMF) trades at a trailing P/E of 0.6, forward P/E of 0.1. Trailing earnings yield is 169.49%, forward earnings yield 909.09%.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.6); earnings yield beats bond yields (169.49%).
- Forward P/E 0.1 (down from trailing 0.6) — analysts expect earnings to grow, which would improve the valuation.
- Trailing Earnings Yield 169.49% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 909.09% as earnings recover.
Overall SharesGrow Score: 71/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ALPMF
Valuation Multiples
P/E (TTM)0.6
Forward P/E0.1
PEG Ratio0.00
Forward PEG0.00
P/B Ratio0.00
P/S Ratio0.02
EV/EBITDA0.0
Per Share Data
EPS (TTM)$28.24
Forward EPS (Est.)$154.44
Book Value / Share$0.00
Revenue / Share$1,064.08
FCF / Share$0.00
Yields & Fair Value
Earnings Yield169.49%
Forward Earnings Yield909.09%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$89.62 |
$1.37T |
$193.69B |
14.1% |
| 2017 |
$103.55 |
$1.31T |
$218.7B |
16.7% |
| 2018 |
$81.02 |
$1.3T |
$164.68B |
12.7% |
| 2019 |
$114.94 |
$1.31T |
$222.27B |
17% |
| 2020 |
$104.08 |
$1.3T |
$195.41B |
15% |
| 2021 |
$64.90 |
$1.25T |
$120.59B |
9.7% |
| 2022 |
$67.05 |
$1.3T |
$124.09B |
9.6% |
| 2023 |
$54.09 |
$1.52T |
$98.71B |
6.5% |
| 2024 |
$9.47 |
$1.6T |
$17.05B |
1.1% |
| 2025 |
$28.24 |
$1.91T |
$50.75B |
2.7% |
